The AKT kinase is activated in multiple myeloma tumor cells.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Blood

• Publication date

  2001-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V98.9.2853PMID 11675360
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of PTEN expression leading to high Akt activation in human multiple myelomas.

  2000cited by this paper
• The Phosphatidylinositol 3-Kinase / AKT Kinase Pathway in Multiple Myeloma Plasma Cells : Roles in Cytokine-dependent Survival and Proliferative Responses 1

  2000cited by this paper
• The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.

  2000cited by this paper
• Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

  1999cited by this paper
• BCL-X expression in multiple myeloma: possible indicator of chemoresistance.

  1998cited by this paper
• IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

  1997cited by this paper
• Multiple myeloma cells are protected against dexamethasone‐induced apoptosis by insulin‐like growth factors

  1997cited by this paper
• Identification and Cloning of the Membrane-associated Serine Protease, Hepsin, from Mouse Preimplantation Embryos*

  1997cited by this paper
• Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.

  1997cited by this paper
• Role of Translocation in the Activation and Function of Protein Kinase B*

  1997cited by this paper
• Interleukin 3-dependent survival by the Akt protein kinase.

  1997cited by this paper
• Interleukin-6 inhibits apoptosis of malignant plasma cells.

  1995cited by this paper
• The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.

  1995cited by this paper
• Response patterns of purified myeloma cells to hematopoietic growth factors.

  1989cited by this paper
• Localized and indolent myeloma.

  1980cited by this paper
• Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

  1978cited by this paper

• The importance of autophagy in multiple myeloma.

  2025cites this paper
• MAMDC2‐AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma

  2025cites this paper
• DTX3L E3 ligase: Molecular functions, regulatory mechanisms, and potential as a novel cancer biomarker and therapeutic target.

  2025cites this paper
• Exploring the promise of regulator of G Protein Signaling 20: insights into potential mechanisms and prospects across solid cancers and hematological malignancies

  2024cites this paper
• A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets.

  2024cites this paper
• Autophagy-related mechanisms for treatment of multiple myeloma

  2023cites this paper
• STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling

  2023cites this paper
• SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma

  2022cites this paper
• AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity

  2022cites this paper
• SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma

  2022cites this paper
• Brucein D imparts a growth inhibitory effect in multiple myeloma cells by abrogating the Akt‐driven signaling pathway

  2022influential citation
• Pathway-Directed Therapy in Multiple Myeloma

  2021cites this paper
• Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway

  2021cites this paper
• Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma

  2021cites this paper
• AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.

  2020cites this paper
• Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.

  2020cites this paper
• Targeting AKT elicits tumor suppressive functions of FOXO transcription factors and GSK3 kinase in Multiple Myeloma

  2019cites this paper
• Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma.

  2019cites this paper
• Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment

  2018cites this paper
• Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.

  2018cites this paper
• Role of Jagged in multiple myeloma-associated angiogenesis

  2018cites this paper
• Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation

  2018cites this paper
• Caractérisation et généralisation de l’implication de la voie NOTCH cytoplasmique au cours des processus de transition épithélio-mésenchymateuse chez l’embryon de poulet

  2018cites this paper
• CIP 2 Aand SETBP 1-mediated PP 2 A inhibition reveals AKT S 473 phosphorylation to be a new biomarker in AML

  2018cites this paper
• Pharmacologic inhibition of AKT leads to cell death in relapsed multiple myeloma.

  2018cites this paper
• CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

  2018cites this paper
• MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway

  2017cites this paper
• Novel investigational drugs active as single agents in multiple myeloma

  2017cites this paper
• PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment

  2017cites this paper
• Overexpression of CIP2A is associated with poor prognosis in multiple myeloma

  2017cites this paper
• Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

  2017cites this paper
• Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells

  2017cites this paper
• Gr upSM Interleukin-6 as a Therapeutic Target on Human Cancer

  2017cites this paper
• Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation

  2017cites this paper
• Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways

  2017cites this paper
• PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242

  2017cites this paper
• Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma

  2016cites this paper
• Adrenomedullin in the growth modulation and differentiation of acute myeloid leukemia cells.

  2016cites this paper
• Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT

  2016cites this paper
• SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism

  2016cites this paper
• The Role of PI3K/AKT/mTOR Inhibitors in the Treatment of Hematological Malignancies

  2016cites this paper
• Cancerous Inhibitor of PP2A Silencing Inhibits Proliferation and Promotes Apoptosis in Human Multiple Myeloma Cells

  2016cites this paper
• Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma

  2016cites this paper
• Exogenous hydrogen sulfide exerts proliferation, anti-apoptosis, migration effects and accelerates cell cycle progression in multiple myeloma cells via activating the Akt pathway.

  2016cites this paper
• Regulation of Cancer Cell Behavior by the Small GTPase Rab13*

  2016cites this paper
• The resistance to bortezomib (BTZ) in multiple myeloma (MM) is partly due to AKT activation and the upregulation of survivin induced by BTZ, which are the targets of ASA

  2016cites this paper
• Rab13 and the Regulation of Cancer Cell Behavior

  2016cites this paper
• Interleukin-6 as a Therapeutic Target

  2015influential citation
• mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein

  2015cites this paper
• Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells

  2015cites this paper
• Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs

  2015cites this paper
• Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Speci fi c Inhibition of RTKs

  2015cites this paper
• Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells

  2015cites this paper
• Cyclophilin A as a downstream effector of PI3K/Akt signalling pathway in multiple myeloma cells

  2015cites this paper
• Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells

  2015cites this paper
• Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines

  2015cites this paper
• Cap-Independent Translation in Hematological Malignancies

  2015cites this paper
• Potent anti‐tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma

  2015cites this paper
• Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

  2014cites this paper
• Cancer Biology and Signal Transduction Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC 1 Inhibition as an Antimyeloma Strategy

  2014cites this paper
• Novel targeted agents in the treatment of multiple myeloma.

  2014cites this paper
• PI3K‐dependent multiple myeloma cell survival is mediated by the PIK3CA isoform

  2014cites this paper
• Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

  2014cites this paper
• Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.

  2014cites this paper
• Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton

  2014cites this paper
• PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma‐induced resistance

  2014cites this paper
• The role of the orphan G protein-coupled receptor 37 (GPR37) in multiple myeloma cells.

  2014cites this paper
• Development of Protease-Resistant β-Hairpin Peptides for the Detection of Enzymatic Activity in Cancer Cells

  2014cites this paper
• Molecularly Targeted Therapies in Multiple Myeloma

  2014cites this paper
• Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta‐catenin pathway

  2014cites this paper
• PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.

  2014influential citation
• AKT as a therapeutic target in multiple myeloma

  2014influential citation
• Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization

  2014cites this paper
• Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy

  2014cites this paper
• A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo

  2013cites this paper
• Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma

  2013influential citation
• associated with Stat3 activation INA-6 cells reveal a Bcl-2-family-independent survival pathway closely Interleukin-6-dependent gene expression profiles in multiple myeloma

  2013cites this paper
• Advances in Biology and Therapy of Multiple Myeloma

  2013cites this paper
• Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma

  2013cites this paper
• Arsenic Trioxide-Enhanced, Matrine-Induced Apoptosis in Multiple Myeloma Cell Lines

  2013cites this paper
• EGFR inhibitor BIBU induces apoptosis and defective autophagy in glioma cells

  2013cites this paper
• multiple myeloma cells in a xenograft model In vivo anti-tumor effects of the mTOR inhibitor, CCI-779, against human

  2013cites this paper
• Genetic and pharmacological evidence that mTOR targeting outweighs mTORC 1 inhibition as an antimyeloma strategy

  2013cites this paper
• Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells.

  2013cites this paper
• The mTOR Pathway in Multiple Myeloma

  2013cites this paper
• Deguelin, a natural rotenoid, inhibits mouse myeloma cell growth in vitro via induction of apoptosis.

  2012cites this paper
• miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

  2012cites this paper
• Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

  2012cites this paper
• Microenvironment and Immunology Bioactivity and Prognostic Signi fi cance of Growth Differentiation Factor GDF 15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma

  2012cites this paper
• Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations

  2012cites this paper
• Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

  2012cites this paper
• Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype

  2012cites this paper
• Black tea polyphenols induce human leukemic cell cycle arrest by inhibiting Akt signaling

  2012cites this paper
• Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.

  2011cites this paper
• Mammalian target of rapamycin as a target in hematological malignancies

  2011cites this paper
• PTEN, pAKT, and pmTOR Expression and Subcellular Distribution in Primary Renal Cell Carcinomas and Their Metastases

  2011cites this paper
• IL-4 and TAL1 in T-cell acute lymphoblastic leukemia : studies on the participation of microenvironmental cues and cell-autonomous alterations in leukemogenesis

  2011cites this paper
• Biochemical and functional analysis of the T cell growth and survival bioactivities of human red blood cells.

  2011cites this paper
• Acute graft-versus-host disease.

  2011cites this paper
• Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells

  2011cites this paper